These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 3839843)

  • 1. Levamisole as adjuvant to chemotherapy for canine lymphosarcoma.
    MacEwen EG; Hayes AA; Mooney S; Patnaik A; Kurzman I; Hardy WD
    J Biol Response Mod; 1985 Aug; 4(4):427-33. PubMed ID: 3839843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effects of levamisole and surgery on canine mammary cancer.
    MacEwen EG; Harvey HJ; Patnaik AK; Mooney S; Hayes A; Kurzman I; Hardy WD
    J Biol Response Mod; 1985 Aug; 4(4):418-26. PubMed ID: 4031952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981).
    MacEwen EG; Hayes AA; Matus RE; Kurzman I
    J Am Vet Med Assoc; 1987 Mar; 190(5):564-8. PubMed ID: 3558097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy for canine lymphosarcoma.
    Theilen GH; Worley M; Benjamini E
    J Am Vet Med Assoc; 1977 Mar; 170(6):607-10. PubMed ID: 576595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoimmunotherapy for canine lymphosarcoma: a prospective evaluation of specific and nonspecific immunomodulation.
    Weller RE; Theilen GH; Madewell BR; Crow SE; Benjamini E; Villalobos A
    Am J Vet Res; 1980 Apr; 41(4):516-21. PubMed ID: 6893260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic combination chemotherapy of canine lymphosarcoma.
    MacEwen EG; Brown NO; Patnaik AK; Hayes AA; Passe S
    J Am Vet Med Assoc; 1981 Jun; 178(11):1178-81. PubMed ID: 6895078
    [No Abstract]   [Full Text] [Related]  

  • 8. Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia.
    Weller RE; Theilen GH; Madewell BR
    J Am Vet Med Assoc; 1982 Nov; 181(9):891-3. PubMed ID: 6897239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for canine lymphosarcoma.
    Madewell BR
    Am J Vet Res; 1975 Oct; 36(10):1525-8. PubMed ID: 1242622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro immune monitoring of antibody response in dogs given chemoimmunotherapy for lymphoma.
    Jeglum KA; Winters WD; Young KM
    Am J Vet Res; 1989 Apr; 50(4):488-92. PubMed ID: 2712415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
    Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
    J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histologic classification as a prognostic criterion for canine lymphosarcoma.
    Weller RE; Holmberg CA; Theilen GH; Madewell BR
    Am J Vet Res; 1980 Aug; 41(8):1310-4. PubMed ID: 6893792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
    Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
    Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma.
    Jeglum KA; Young KM; Barnsley K; Whereat A; McGrath D; Hutson C
    J Biol Response Mod; 1986 Apr; 5(2):168-75. PubMed ID: 3734843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
    Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
    Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
    Yong W; Zheng W; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uric acid and phosphorus excretion in dogs with lymphosarcoma.
    Page RL; Leifer CE; Matus RE
    Am J Vet Res; 1986 Apr; 47(4):910-2. PubMed ID: 3754406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
    Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin for treatment of canine lymphosarcoma after development of resistance to combination chemotherapy.
    Calvert CA; Leifer CE
    J Am Vet Med Assoc; 1981 Nov; 179(10):1011-2. PubMed ID: 6896200
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.